Your browser is no longer supported. Please, upgrade your browser.
RGEN Repligen Corporation daily Stock Chart
RGEN [NASD]
Repligen Corporation
Index- P/E277.42 EPS (ttm)0.45 Insider Own0.80% Shs Outstand52.14M Perf Week0.56%
Market Cap6.66B Forward P/E94.86 EPS next Y1.32 Insider Trans-32.29% Shs Float48.48M Perf Month6.86%
Income23.20M PEG11.32 EPS next Q0.27 Inst Own90.20% Short Float3.25% Perf Quarter19.00%
Sales285.70M P/S23.32 EPS this Y19.10% Inst Trans0.12% Short Ratio2.35 Perf Half Y26.08%
Book/sh20.52 P/B6.08 EPS next Y16.77% ROA1.80% Target Price141.17 Perf Year45.25%
Cash/sh9.92 P/C12.58 EPS next 5Y24.50% ROE2.30% 52W Range72.32 - 143.93 Perf YTD34.96%
Dividend- P/FCF143.26 EPS past 5Y12.10% ROI2.00% 52W High-13.26% Beta1.08
Dividend %- Quick Ratio14.10 Sales past 5Y33.60% Gross Margin56.50% 52W Low72.62% ATR4.78
Employees761 Current Ratio15.60 Sales Q/Q25.60% Oper. Margin10.90% RSI (14)52.55 Volatility3.57% 3.79%
OptionableYes Debt/Eq0.00 EPS Q/Q6.20% Profit Margin8.10% Rel Volume0.59 Prev Close122.51
ShortableYes LT Debt/Eq0.22 EarningsMay 06 BMO Payout0.00% Avg Volume670.92K Price124.84
Recom1.60 SMA203.73% SMA500.63% SMA20024.79% Volume397,778 Change1.90%
Jun-30-20Reiterated H.C. Wainwright Buy $143 → $151
May-07-20Reiterated H.C. Wainwright Buy $100 → $143
Mar-23-20Reiterated H.C. Wainwright Buy $110 → $100
Nov-15-19Initiated Stifel Buy
Nov-01-19Upgrade First Analysis Sec Outperform → Strong Buy $107 → $110
Oct-15-19Initiated SVB Leerink Outperform $100
Aug-28-19Reiterated First Analysis Sec Outperform $95 → $107
Aug-23-19Resumed Stephens Overweight
Jul-22-19Upgrade H.C. Wainwright Neutral → Buy $110
Dec-17-18Upgrade CL King Neutral → Buy
Nov-12-18Downgrade CL King Buy → Neutral
Sep-26-18Initiated H.C. Wainwright Neutral $49
Dec-08-17Initiated Citigroup Buy $45
Dec-05-17Initiated JP Morgan Overweight $42
Nov-13-17Initiated CL King Buy
Oct-02-17Upgrade First Analysis Sec Equal-Weight → Overweight $47
Jul-21-17Initiated William Blair Outperform
Feb-13-17Upgrade Piper Jaffray Neutral → Overweight
Feb-22-16Initiated Craig Hallum Buy
Nov-06-15Downgrade Jefferies Buy → Hold
Jul-08-20 01:23PM  
Jul-03-20 11:40AM  
08:34AM  
Jun-29-20 07:30AM  
Jun-18-20 03:32PM  
Jun-17-20 11:40AM  
Jun-15-20 06:14PM  
07:30AM  
Jun-12-20 08:36AM  
Jun-05-20 11:31AM  
May-28-20 11:40AM  
11:34AM  
May-27-20 09:15AM  
May-13-20 12:20PM  
May-08-20 10:23AM  
May-06-20 11:02PM  
03:40PM  
11:48AM  
09:15AM  
07:30AM  
May-05-20 10:19AM  
Apr-29-20 12:33PM  
Apr-23-20 02:22PM  
Apr-22-20 04:22PM  
07:30AM  
Apr-21-20 04:31PM  
11:42AM  
Apr-11-20 10:15AM  
Apr-05-20 09:03PM  
Apr-01-20 06:00AM  
Mar-21-20 11:30AM  
Mar-19-20 04:17PM  
Mar-12-20 10:58AM  
Feb-28-20 11:10AM  
Feb-27-20 07:30AM  
Feb-21-20 10:32AM  
Feb-20-20 11:50PM  
08:45AM  
07:30AM  
07:06AM  
Feb-19-20 12:45PM  
Feb-13-20 12:31PM  
Feb-06-20 07:30AM  
Feb-04-20 06:41PM  
Jan-30-20 11:10AM  
Jan-24-20 10:15AM  
Jan-17-20 08:45AM  
Jan-10-20 12:43PM  
Jan-08-20 04:06PM  
Jan-07-20 07:30AM  
Dec-11-19 02:04PM  
Dec-09-19 11:30AM  
Dec-08-19 07:11PM  
Dec-06-19 12:45PM  
Dec-04-19 12:00PM  
Dec-02-19 04:32PM  
Nov-14-19 09:30AM  
Nov-06-19 04:08AM  
Nov-01-19 02:49PM  
Oct-31-19 09:15AM  
07:30AM  
Oct-30-19 11:49AM  
Oct-24-19 03:34PM  
10:32AM  
Oct-23-19 10:29AM  
Oct-03-19 07:54PM  
Sep-30-19 11:12AM  
Sep-24-19 05:38PM  
Sep-23-19 06:41AM  
Sep-14-19 06:31AM  
Sep-11-19 07:15PM  
Sep-09-19 02:19PM  
Sep-06-19 06:00PM  
Aug-30-19 06:47AM  
Aug-28-19 07:11AM  
Aug-27-19 03:16PM  
Aug-16-19 07:11AM  
Aug-08-19 10:13AM  
Aug-05-19 10:39AM  
06:37AM  
Aug-02-19 11:54AM  
10:53AM  
02:24AM  
Aug-01-19 12:02PM  
12:00PM  
09:25AM  
07:30AM  
07:02AM  
Jul-30-19 10:58AM  
Jul-29-19 07:58AM  
Jul-25-19 11:25AM  
10:33AM  
Jul-23-19 04:01PM  
10:56AM  
Jul-19-19 07:42PM  
09:30AM  
Jul-18-19 11:18AM  
Jul-17-19 08:10AM  
12:14AM  
Jul-15-19 04:02PM  
Repligen Corporation develops and commercializes bioprocessing technologies and systems that are used in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA kits, which are analytical test kits to quantitate the proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber module-bag-tubing sets. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. It has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DAWES KAREN ADirectorJun 18Sale115.2018,7052,154,851100,734Jun 22 04:42 PM
Hunt AnthonyChief Executive OfficerMay 21Option Exercise24.1050,0391,206,140277,194May 26 09:27 PM
Hunt AnthonyChief Executive OfficerMay 21Sale139.7746,9536,562,409230,241May 26 09:27 PM
DAWES KAREN ADirectorMay 20Sale139.4451772,093119,439May 21 09:08 PM
BARTHELEMY NICOLASDirectorMay 18Option Exercise67.712,109142,8005,673May 26 09:24 PM
BARTHELEMY NICOLASDirectorMay 18Sale142.533,009428,8732,664May 26 09:24 PM
DAWES KAREN ADirectorMay 18Sale137.781,600220,448119,956May 19 08:46 PM
KURIYEL RALFSenior VP, R&DMay 15Sale140.6943561,20026,089May 19 08:54 PM
Snodgres JonChief Financial OfficerMay 15Sale140.4366092,68432,267May 19 08:47 PM
KURIYEL RALFSenior VP, R&DMay 13Option Exercise33.268,000266,04034,524May 15 05:37 PM
Snodgres JonChief Financial OfficerMay 13Option Exercise30.7512,194374,95648,321May 15 05:41 PM
KURIYEL RALFSenior VP, R&DMay 13Sale127.808,0001,022,37326,524May 15 05:37 PM
Snodgres JonChief Financial OfficerMay 13Sale128.7415,3941,981,87532,927May 15 05:41 PM
BARTHELEMY NICOLASDirectorApr 22Option Exercise42.071,65269,5005,725Apr 24 05:22 PM
BARTHELEMY NICOLASDirectorApr 22Sale109.992,688295,6533,037Apr 24 05:22 PM
DAWES KAREN ADirectorApr 21Option Exercise3.3011,80038,940120,834Apr 22 06:07 PM
DAWES KAREN ADirectorApr 20Option Exercise3.308,20027,060121,234Apr 22 06:07 PM
DAWES KAREN ADirectorApr 20Sale104.5712,2001,275,717109,034Apr 22 06:07 PM
BARTHELEMY NICOLASDirectorApr 03Option Exercise42.071,65269,5006,761Apr 06 07:34 PM
BARTHELEMY NICOLASDirectorApr 03Sale99.992,688268,7734,073Apr 06 07:34 PM
Cox JohnDirectorMar 24Sale96.721,858179,706923Mar 26 07:31 PM
Cox JohnDirectorMar 18Option Exercise24.3726,736651,60329,517Mar 20 04:25 PM
Cox JohnDirectorMar 18Sale95.2726,7362,547,0352,781Mar 20 04:25 PM
RYAN THOMAS F JRDirectorMar 16Option Exercise40.421,00040,4152,923Mar 18 05:10 PM
RYAN THOMAS F JRDirectorMar 16Sale91.481,00091,4801,923Mar 18 05:10 PM
RYAN THOMAS F JRDirectorMar 04Option Exercise41.704,796200,0156,719Mar 05 05:53 PM
Cox JohnDirectorMar 04Option Exercise12.9110,000129,10012,781Mar 05 05:52 PM
Hunt AnthonyChief Executive OfficerMar 04Sale90.1312,3001,108,599230,241Mar 05 05:50 PM
Snodgres JonChief Financial OfficerMar 04Sale90.391,04594,45836,127Mar 05 05:53 PM
RYAN THOMAS F JRDirectorMar 04Sale88.824,796425,9811,923Mar 05 05:53 PM
Cox JohnDirectorMar 04Sale93.3910,000933,9002,781Mar 05 05:52 PM
KURIYEL RALFSenior VP, R&DMar 04Sale90.762,555231,88826,524Mar 05 05:53 PM
KURIYEL RALFSenior VP, R&DMar 03Sale88.3545039,75829,079Mar 05 05:53 PM
RYAN THOMAS F JRDirectorMar 03Sale85.722,225190,7271,923Mar 05 05:53 PM
Snodgres JonChief Financial OfficerMar 03Sale88.1861053,79037,172Mar 05 05:53 PM
Hunt AnthonyChief Executive OfficerMar 03Sale88.222,190193,194242,541Mar 05 05:50 PM
Snodgres JonChief Financial OfficerFeb 26Sale86.221,10094,83731,096Feb 27 05:39 PM
Hunt AnthonyChief Executive OfficerFeb 26Sale86.513,475300,627226,148Feb 27 05:39 PM
KURIYEL RALFSenior VP, R&DFeb 26Sale86.6019516,88726,313Feb 27 05:38 PM
Hunt AnthonyChief Executive OfficerFeb 25Option Exercise25.0321,945549,190231,148Feb 27 05:39 PM
Hunt AnthonyChief Executive OfficerFeb 25Sale91.5611,7351,074,447219,413Feb 27 05:39 PM
Cox JohnDirectorFeb 24Sale92.814,455413,4552,781Feb 26 04:27 PM
DAWES KAREN ADirectorFeb 21Sale98.704,000394,793113,034Feb 24 05:51 PM
Snodgres JonChief Financial OfficerDec 05Option Exercise25.273,95799,98032,196Dec 09 04:17 PM
Hunt AnthonyChief Executive OfficerSep 19Option Exercise16.5520,000331,000223,013Sep 23 06:02 PM
Hunt AnthonyChief Executive OfficerSep 19Sale82.893,600298,390219,413Sep 23 06:02 PM
Hunt AnthonyChief Executive OfficerSep 09Sale82.4012,094996,521203,013Sep 11 04:58 PM